Thyroid Cancer: Current Molecular Perspectives

Overview

Journal J Oncol

Specialty Oncology

Date 2010 Apr 7

PMID 20369062

Citations 11

Authors

Francesca Giusti

Alberto Falchetti

Francesco Franceschelli

Francesca Marini

Annalisa Tanini

Maria Luisa Brandi

Affiliations

Soon will be listed here.

Abstract

The thyroid cancer is a rare oncological entity, representing no more than 1% of all human malignant neoplasms. Recently, it has been demonstrated a sharp increase in incidence of differentiated thyroid carcinoma, equally occurring in both sexes. So far, multiple genetic alterations have been identified in differentiated thyroid carcinoma, leading to investigate the clinical utility of genetic studies. In particular, molecular genetic approaches searching for gene mutations in the material collected by fine needle ago-biopsy may have a particular utility in small nodules and in those specimens with an indeterminate cytology. The expansion of knowledge about genetic mutations occurring in different thyroid tumors has characterized recent years, allowing the identification of a correlation between specific mutations and phenotypic characteristics of thyroid cancers, essential for their prognosis. This review will briefly report on the histological features and the new entity represented by thyroid microcarcinoma and will focus on both environmental and genetic aspects associated with the occurrence of thyroid cancer.

Citing Articles

The necessity of thyroid-stimulating hormone suppression therapy for low-risk differentiated thyroid carcinoma following hemithyroidectomy: A systematic review and meta-analysis.

Wang X, Ye Y, Amdulla M, Ren C, Liu Y, Ni S Heliyon. 2024; 10(23):e40574.

PMID: 39654735 PMC: 11626026. DOI: 10.1016/j.heliyon.2024.e40574.

Papillary Thyroid Cancer Remodels the Genetic Information Processing Pathways.

Iacobas D, Iacobas S Genes (Basel). 2024; 15(5).

PMID: 38790250 PMC: 11120757. DOI: 10.3390/genes15050621.

Predictive factors of contralateral occult carcinoma in patients with papillary thyroid carcinoma: a retrospective study.

Chen X, Zhong Z, Song M, Yuan J, Huang Z, Du J Gland Surg. 2020; 9(4):872-878.

PMID: 32953595 PMC: 7475348. DOI: 10.21037/gs-19-157.

Clinicopathological Significance of Overall Frequency of Allelic Loss (OFAL) in Lesions Derived from Thyroid Follicular Cell.

Migdalska-Sek M, Czarnecka K, Kusinski M, Pastuszak-Lewandoska D, Nawrot E, Kuzdak K Mol Diagn Ther. 2019; 23(3):369-382.

PMID: 30747408 PMC: 6548761. DOI: 10.1007/s40291-019-00387-0.

Matrine inhibits TPC-1 human thyroid cancer cells via the miR-21/PTEN/Akt pathway.

Zhao L, Zhang X, Cui S Oncol Lett. 2018; 16(3):2965-2970.

PMID: 30127885 PMC: 6096072. DOI: 10.3892/ol.2018.9006.

References

Viglietto G, Chiappetta G, Martinez-Tello F, FUKUNAGA F, Tallini G, Rigopoulou D . RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene. 1995; 11(6):1207-10. View

Domingues R, Mendonca E, Sobrinho L, Bugalho M . Searching for RET/PTC rearrangements and BRAF V599E mutation in thyroid aspirates might contribute to establish a preoperative diagnosis of papillary thyroid carcinoma. Cytopathology. 2005; 16(1):27-31. DOI: 10.1111/j.1365-2303.2004.00223.x. View

Galang C, Hauser C . Cooperative DNA binding of the highly conserved human Hox 2.1 homeodomain gene product. New Biol. 1992; 4(5):558-68. View

Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven T, Roeher H . Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med. 2003; 349(16):1517-25. DOI: 10.1056/NEJMoa012915. View

Israel A, Sharan R, Ruppin E, Galun E . Increased microRNA activity in human cancers. PLoS One. 2009; 4(6):e6045. PMC: 2698213. DOI: 10.1371/journal.pone.0006045. View

Mulligan L, Marsh D, Robinson B, Schuffenecker I, Zedenius J, Lips C . Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med. 1995; 238(4):343-6. DOI: 10.1111/j.1365-2796.1995.tb01208.x. View

Carlomagno F, Vitagliano D, Guida T, Basolo F, Castellone M, Melillo R . Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). J Clin Endocrinol Metab. 2003; 88(4):1897-902. DOI: 10.1210/jc.2002-021278. View

Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B . BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003; 95(8):625-7. DOI: 10.1093/jnci/95.8.625. View

Maximo V, Botelho T, Capela J, Soares P, Lima J, Taveira A . Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid. Br J Cancer. 2005; 92(10):1892-8. PMC: 2361763. DOI: 10.1038/sj.bjc.6602547. View

10.

Fugazzola L, Mannavola D, Cirello V, Vannucchi G, Muzza M, Vicentini L . BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf). 2004; 61(2):239-43. DOI: 10.1111/j.1365-2265.2004.02089.x. View

11.

Harach H, Franssila K, Wasenius V . Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study. Cancer. 1985; 56(3):531-8. DOI: 10.1002/1097-0142(19850801)56:3<531::aid-cncr2820560321>3.0.co;2-3. View

12.

Suzuki T, Matsuo K, Hasegawa Y, Hiraki A, Kawase T, Tanaka H . Anthropometric factors at age 20 years and risk of thyroid cancer. Cancer Causes Control. 2008; 19(10):1233-42. DOI: 10.1007/s10552-008-9194-x. View

13.

Nikiforova M, Kimura E, Gandhi M, Biddinger P, Knauf J, Basolo F . BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003; 88(11):5399-404. DOI: 10.1210/jc.2003-030838. View

14.

Hunt J, Yim J, Tometsko M, Finkelstein S, Swalsky P, Carty S . Loss of heterozygosity of the VHL gene identifies malignancy and predicts death in follicular thyroid tumors. Surgery. 2003; 134(6):1043-7. DOI: 10.1016/j.surg.2003.07.023. View

15.

Esapa C, Johnson S, Kendall-Taylor P, Lennard T, Harris P . Prevalence of Ras mutations in thyroid neoplasia. Clin Endocrinol (Oxf). 1999; 50(4):529-35. DOI: 10.1046/j.1365-2265.1999.00704.x. View

16.

Tallini G, Asa S . RET oncogene activation in papillary thyroid carcinoma. Adv Anat Pathol. 2001; 8(6):345-54. DOI: 10.1097/00125480-200111000-00005. View

17.

Hara H, Fulton N, Yashiro T, Ito K, DeGroot L, Kaplan E . N-ras mutation: an independent prognostic factor for aggressiveness of papillary thyroid carcinoma. Surgery. 1994; 116(6):1010-6. View

18.

Hoffmann S, Burchert A, Wunderlich A, Wang Y, Lingelbach S, Hofbauer L . Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines. Endocrine. 2007; 31(2):105-13. DOI: 10.1007/s12020-007-0008-9. View

19.

Dal Maso L, La Vecchia C, Franceschi S, Preston-Martin S, Ron E, Levi F . A pooled analysis of thyroid cancer studies. V. Anthropometric factors. Cancer Causes Control. 2000; 11(2):137-44. DOI: 10.1023/a:1008938520101. View

20.

Karga H, Lee J, VICKERY JR A, Thor A, Gaz R, Jameson J . Ras oncogene mutations in benign and malignant thyroid neoplasms. J Clin Endocrinol Metab. 1991; 73(4):832-6. DOI: 10.1210/jcem-73-4-832. View